Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis.
Gagelmann N, Salit RB, Schroeder T, Badbaran A, Rautenberg C, Panagiota V, Wolschke C, Thol F, Cassinat B, Robin M, Heuser M, Reinhardt HC, Scott BL, Kröger N. Gagelmann N, et al. Among authors: cassinat b. Hemasphere. 2022 Sep 30;6(10):e784. doi: 10.1097/HS9.0000000000000784. eCollection 2022 Oct. Hemasphere. 2022. PMID: 36204690 Free PMC article.
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuk F, Socié G, Kröger N. Robin M, et al. Among authors: cassinat b. Biol Blood Marrow Transplant. 2016 Jul;22(7):1206-1211. doi: 10.1016/j.bbmt.2016.02.019. Epub 2016 Mar 10. Biol Blood Marrow Transplant. 2016. PMID: 26970380 Free article.
Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?
Ruggiu M, Cassinat B, Kiladjian JJ, Raffoux E, Giraudier S, Robin M, Itzykson R, Clappier E, Michonneau D, de Fontbrune FS, de Latour RP, Ades L, Socié G. Ruggiu M, et al. Among authors: cassinat b. Biol Blood Marrow Transplant. 2020 Jun;26(6):1160-1170. doi: 10.1016/j.bbmt.2020.02.019. Epub 2020 Feb 28. Biol Blood Marrow Transplant. 2020. PMID: 32119970 Free article.
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.
Robin M, Porcher R, Orvain C, Bay JO, Barraco F, Huynh A, Charbonnier A, Forcade E, Chantepie S, Bulabois C, Yakoub-Agha I, Detrait M, Michonneau D, Turlure P, Raus N, Boyer F, Suarez F, Vincent L, Guyen SN, Cornillon J, Villate A, Dupriez B, Cassinat B, Rolland V, Schlageter MH, Socié G, Kiladjian JJ. Robin M, et al. Among authors: cassinat b. Bone Marrow Transplant. 2021 Aug;56(8):1888-1899. doi: 10.1038/s41409-021-01252-7. Epub 2021 Mar 25. Bone Marrow Transplant. 2021. PMID: 33767402 Free PMC article. Clinical Trial.
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis.
Gagelmann N, Wolschke C, Salit RB, Schroeder T, Ditschkowski M, Panagiota V, Cassinat B, Thol F, Badbaran A, Robin M, Reinhardt HC, Ayuk F, Heuser M, Scott BL, Kröger N. Gagelmann N, et al. Among authors: cassinat b. Blood Adv. 2022 Feb 22;6(4):1222-1231. doi: 10.1182/bloodadvances.2021006827. Blood Adv. 2022. PMID: 35051996 Free PMC article.
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation.
Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol F, Wolschke C, Robin M, Heuser M, Rubio MT, Maciejewski JP, Reinhardt HC, Scott BL, Kröger N. Gagelmann N, et al. Among authors: cassinat b. Blood. 2023 Jun 8;141(23):2901-2911. doi: 10.1182/blood.2023019630. Blood. 2023. PMID: 36940410
166 results